Furthermore, preliminary PBMC cultures established from breast cancer patients confirm that our culture system and antigen discovery algorithm can be extended successfully to patients with MUC1- and HER2-expressing malignancies (Supplemental Figure S5A). This evidence concerns the gene ERBB2 and breast carcinoma.